Seizert Capital Partners, LLC Eli Lilly & CO Transaction History

Seizert Capital Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 08, 2021	SELL	$130.46 - $172.63 $1.69 Million - $2.24 Million	-12,972 Closed	0 $0
Q3 2020 Nov 03, 2020	BUY	$146.22 - $169.13 $384,266 - $444,473	2,628 Added 25.41%	12,972 $1.92 Million
Q2 2020 Aug 06, 2020	BUY	$136.42 - $164.18 $487,837 - $587,107	3,576 Added 52.84%	10,344 $1.7 Million
Q1 2020 May 05, 2020	SELL	$119.05 - $147.35 $114,049 - $141,161	-958 Reduced 12.4%	6,768 $939,000
Q4 2019 Feb 10, 2020	SELL	$106.92 - $132.43 $93,020 - $115,214	-870 Reduced 10.12%	7,726 $1.02 Million
Q3 2019 Nov 07, 2019	BUY	$106.79 - $116.16 $917,966 - $998,511	8,596 New	8,596 $961,000

4,010

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $756B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Seizert Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Seizert Capital Partners, LLC with notifications on news.